GMR CAR-T cells (E21R)

GMR CAR-T cells (E21R) is an experimental adoptive cell therapy consisting of autologous T cells engineered to express a chimeric antigen receptor (CAR) targeting the granulocyte-macrophage colony-stimulating factor receptor (GMR) complex, specifically the CD116/CD131 heterodimer. Developed by researchers at Shinshu University, the therapy utilizes a non-viral piggyBac transposon system for gene transfer. The CAR construct features a mutated human GM-CSF ligand as the antigen-binding domain, specifically incorporating a glutamate-to-arginine substitution at residue 21 (E21R) and a G4S spacer to enhance binding affinity and anti-tumor activity while minimizing off-target effects. It is primarily being investigated for the treatment of relapsed or refractory acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML), where CD116 is frequently overexpressed.

Other names

mutated GM-CSF-based CAR T-cellsE21R GMR CAR-TE-21R GMR CAR-TE 21R GMR CAR-T